ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01

Its studies are mostly in Colorectal Neoplasms, led by Radiopharm Theranostics.

Furthest: phase 2, since Sep 11, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Radiopharm Theranostics11 open or runningphase 2since Sep 11, 2025Sep 11, 2025Dec 2027phase 2 · NCT07189871

Also a collaborator on its studies: Medpace.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2025First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07189871 · 61 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07189871

TargetBeta

CD276 →read by rule
“A radioimmunoconjugate consisting of a monoclonal antibody directed against the 4Ig isoform of the surface immunomodulatory glycoprotein human B7-homolog 3 (B7-H3, CD276) ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 36
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07189871Colorectal Neoplasms · United States2RecruitingDec 202761

How it is read

Names in the registry

  • “177Lu-BetaBart”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.